Rallybio Corp (RLYB) USD0.0001
0.27%- This stock can be held in a
Stocks and Shares ISA
$0.01
(3.97%)$0.01
(3.97%)Company Information
About this company
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, is a C5-targeted Affibody molecule conjugated to polyethylene glycol; RLYB332, is a preclinical antibody designed to inhibit MTP-2, and REV102 Program, is a small molecule inhibitor of ectonucleotide pyrophosphatase/ phosphodiesterase 1(ENPP1).
Key people
Key facts
- EPICRLYB
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS75120L1008
- Market cap$13.34m
- Employees25
- Shares in issue41.61m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.